来源：新浪基金 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调近两个季度，长期看，较多优质标的估值性价 比明显，当前位置建议加大关注。* 再来看港股通医疗板块表现，AI医疗、脑机接口概念股较为活跃，大权重领衔涨势，京东健康、阿里 健康、平安好医生齐涨3%左右，港股通医疗ETF华宝（159137）日线五连阳。 目前AI医疗在C端的渗透正在加速，从智能问诊到慢病管理的应用场景不断拓展，推动阿里健康、京东 健康等港股互联网医疗平台价值重估。 中信建投证券指出，港股器械整体创新属性较强，部分企业的创新产品具有license-out或被并购的可 能。基本面维度，行业内部多数公司经营业绩持续改善，低估值投资价值凸显。事件方面，预计迈瑞医 疗、可孚医疗今年将在港股上市，港股医疗器械板块效应和投资机会或将增多。* 2月9日，港股市场全面反弹，港股医药板块延续修复行情。 信达生物拿下88.5亿美元BD大单，无意外全天领涨，最高涨至8.55%，收涨7.42%，龙头股大受提振， 百济神州涨超3%，石药集团、中国生物制药、三生制药集 ...

2月9日，港股市场全面反弹，港股医药板块延续修复行情。 信达生物拿下88.5亿美元BD大单，无意外全天领涨，最高涨至8.55%，收涨7.42%，龙头股大受提振， 百济神州涨超3%，石药集团、中国生物制药、三生制药集体跟涨。 100%创新药研发标的——港股通创新药ETF（520880）高开后上探2.75%，收涨1.77%成功连阳，一并 站上10日均线，全天成交3.81亿元。 2月8日晚，信达生物公告，公司与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研 发进程。信达将获3.5亿美元首付款，最高可获85亿美元里程碑付款及大中华区以外净销售额梯度分 成。 2025年中国创新药License-out总交易规模达到创纪录的1357亿美元，2026年开年以来重磅合作频出，除 信达外，1月份石药-阿斯利康（185亿美元）、荣昌-艾伯维（56亿美元）两笔超级BD均充分验证国产 创新药管线的全球价值。 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调近两个季度，长期看，较多优质标的估值性价 比明显，当前位置建议加大 ...

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1]. Core Insights - The report highlights the acceleration of policy support for the optimization and transformation of the traditional Chinese medicine (TCM) industry, benefiting leading TCM companies [4][15]. - The report emphasizes the potential benefits for innovative drug companies due to the establishment of a collaborative innovation system and the promotion of new drug approvals [5][15]. - The report notes that the A-share pharmaceutical and biotechnology sector has shown a slight increase of 0.14% in the week from February 2 to February 6, 2026, outperforming the CSI 300 index by 1.47 percentage points [6][18]. Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 8350.08, with a weekly high of 9323.49 and a low of 6876.88 [1]. Recent Market Performance - The A-share pharmaceutical sector outperformed the CSI 300 index and the ChiNext index during the week, ranking 15th among 31 sub-industries [6][18]. - The TCM sector ranked first among sub-sectors with a weekly increase of 2.56%, while other biopharmaceutical sectors experienced a decline [18]. Policy Developments - The Ministry of Industry and Information Technology and other departments issued a plan for the high-quality development of the TCM industry from 2026 to 2030, aiming to establish a collaborative development system and support leading TCM enterprises [4][15]. - The plan includes fostering a batch of innovative TCM drugs and enhancing the protection of intellectual property for traditional brands [5][16][17]. Investment Recommendations 1. **Innovative Drugs**: The report suggests that innovative drug companies remain a strong investment choice, with a focus on companies with high certainty and low disruption expectations, such as Innovent Biologics and 3SBio [7][21]. 2. **Medical Devices**: The medical device sector is expected to see a recovery in profits, with a focus on companies like Mindray and Kangji Medical, as the impact of centralized procurement diminishes [23][24]. 3. **Traditional Chinese Medicine**: Companies like Yiling Pharmaceutical and Tianjin Zhongxin Pharmaceutical are expected to benefit from policies supporting TCM and the clearing of high inventory levels [28][29][30]. 4. **AI in Healthcare**: Companies involved in AI applications in pharmaceuticals and diagnostics, such as iCarbonX and Huada Gene, are anticipated to benefit from advancements in AI technology [32][34].

Group 1 - Global assets are experiencing significant volatility at the beginning of 2026, with precious metals like gold and silver showing notable pullbacks after initial gains [1][19] - The market is focused on how to allocate assets after the turbulence, particularly regarding fixed income assets as a long-term core allocation [1][19] - The current political climate is shifting towards a "big fiscal" era, with abundant liquidity leading to asset bubbles, particularly in the U.S. stock market [19][21] Group 2 - The U.S. market is entering a bubble phase similar to 1999, with expectations for gold to reach new highs while the dollar index declines [2][19] - Key risks for 2026 include potential loss of Federal Reserve independence, aggressive monetary easing leading to inflation, and possible internal strife in the U.S. [2][19] - If risks arise outside the U.S., dollar assets may serve as a safe haven, similar to the situation in 1998 [2][19] Group 3 - Investors are advised to adopt a diversified asset allocation strategy for 2026, including A-shares, Hong Kong stocks, U.S. stocks, commodities, and bonds, with a focus on a "core + satellite" structure [4][21] - The core investment should be in the CSI A500 ETF, which is expected to outperform traditional indices, while satellite investments should include technology growth and cash flow/dividend assets [4][21] - The main theme for 2026 remains artificial intelligence, with a focus on sectors like communication and semiconductor ETFs [4][21] Group 4 - In equity investments, there is optimism for a shift from valuation recovery to profit improvement, particularly in sectors like non-ferrous metals, new energy, and chemicals [8][24] - Fixed income investments are expected to maintain a positive stance, with a focus on credit strategies and potential trading opportunities as the market adjusts [8][24] - The credit bond market is anticipated to experience wide fluctuations, with a focus on short-term strategies and market sentiment [10][26] Group 5 - The economic environment remains under pressure, with weak consumer demand and a declining real estate market, leading to low inflation expectations [12][28] - Monetary policy is expected to remain accommodative, with potential for further rate cuts and reserve requirement reductions in 2026 [12][28] - Institutional behavior indicates a strong performance in equity markets, but challenges remain for public funds and banks in expanding their balance sheets [12][28]

板块表现： 证券研究报告 医药生物 行业定期报告 hyzqdatemark 2026 年 02 月 09 日 刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com 分子胶：撬动"不可成药"靶点的创新药新范式 投资评级： 看好（维持） ——医药行业周报（26/2/2-26/2/6） 投资要点： 请务必仔细阅读正文之后的评级说明和重要声明 证券分析师 联系人 本周医药市场表现分析：2 月 2 日至 2 月 6 日，医药指数上涨 0.14%，相对沪深 300 指数超 额收益为 1.47%。上周市场风格有所变化，白酒等底部消费类资产表现较好，医药行业中的 医疗服务、中药亦有表现。另外，经历短期波动消化后，创新药板块已显现企稳回暖迹象。 我们建议精选基本面强劲、前期调整充分的创新药个股，看好未来股价有望走出新高度，同 时建议积极关注医疗新科技等板块，以及 26 年困境反转的底部个股。1）创新药建议关注，A 股）恒瑞医药、信立泰、泽璟制药、热景生物、科伦药业、上海谊众、康弘药业、华纳药厂、 前沿生物、福元医药、苑东生物、昂利康；港股）中国生物制药、三生制药、信达生物、康 方生物 ...

Group 1 - The core viewpoint is that 2026 is expected to be a bull market, characterized by significant trading volume, a surge in new account openings, and ample liquidity due to low interest rates and maturing deposits [7][10][11] - The market structure is described as "unconventional," with a lack of incremental funds for actively managed products, leading to extreme liquidity and a one-sided market performance [3][15][16] - The current market resembles early 2007, where small-cap stocks are performing well while large-cap stocks lag, indicating a potential structural shift may be needed [4][17] Group 2 - The investment strategy emphasizes the importance of understanding the fundamentals, especially in a market with extreme volatility, and suggests a balanced portfolio approach [5][40] - The article highlights the necessity of recognizing the growth potential in AI, arguing that AI investments should not be evaluated solely on immediate revenue but rather as a survival imperative for companies [18][28] - The discussion includes the need for a diversified investment strategy across different markets, including A-shares, Hong Kong stocks, and international markets, to capture growth opportunities [41][42] Group 3 - The article points out that while macroeconomic conditions may be weak, the AI industry presents significant growth opportunities, and companies must invest in AI to avoid being left behind [19][20] - It is noted that major tech companies are increasing their investments in AI, reinforcing the trend's certainty and potential for growth [27][31] - The importance of focusing on the supply chain and production capabilities in the semiconductor sector is emphasized, as domestic companies are expected to drive growth in related industries [30][48]

Core Viewpoint - After several days of adjustments, Hong Kong's tech assets have seen a significant rebound, with sectors such as the internet and innovative pharmaceuticals rising together, particularly highlighted by a more than 30% surge in the large model company Zhiyu [1] Group 1: Market Performance - The Hong Kong Stock Connect Technology ETF (159101.SZ) saw its market price increase by nearly 2% during intraday trading, with holdings like Alibaba, Tencent, SMIC, BYD, Hua Hong, BeiGene, and Xpeng all rising over 2% [1] - The PE-TTM of the Hong Kong Stock Connect Technology ETF is at 21 times, which is significantly lower than other major tech indices such as NASDAQ, ChiNext, and STAR Market, positioned at the 30th percentile of the last 10 years [1] Group 2: Sector Coverage - The index of the Hong Kong Stock Connect Technology ETF has filled the gap in innovative pharmaceuticals while also covering leading companies in internet platforms, smart driving, and innovative drugs, including Alibaba, Tencent, BYD, BeiGene, and WuXi Biologics, all of which are eligible for Hong Kong Stock Connect [1] - The ETF is not subject to QDII foreign exchange quota restrictions, providing better liquidity for investors [1] Group 3: Trading Features - The Hong Kong Stock Connect Technology ETF is listed on the Shenzhen Stock Exchange and supports T+0 intraday flexible trading, offering A-share investors a low-threshold option without the need for cross-border accounts or currency exchange [1]

智通财经APP获悉，2月6日，中国证监会国际合作司发布《关于丹诺医药(苏州)股份有限公司境外发行上市及境内未上市股份"全流通"备案通知书》。公司 拟发行不超过12,498,400股境外上市普通股并在香港联合交易所上市。公司49名股东拟将所持合计43,472,926股境内未上市股份转为境外上市股份，并在香港 联合交易所上市流通。 | 索 引 号 | bm56000001/2026-00001529 ਦੇ | | 类 | 结果公 | | --- | --- | --- | --- | --- | | 发布机构 | | 发文日期 | | 2026£ | | 名 称 | 关于丹诺医药（苏州）股份有限公司境外发行上市及境内未上市股份"全流通"备案通知书 | | | | | 文 특 | 国合函〔2026〕299 号 | 主题词 | | | 招股书显示，丹诺医药于2013年注册成立，是一家临近商业化阶段的生物科技公司，专注于发现、开发及商业化差异化的创新药产品，以解决细菌感染及细 菌代谢相关疾病领域的未被满足临床需求。凭借自主开发的多靶点偶联分子技术，公司致力于为患者提供最佳治疗方案，以克服传统治疗的局限性并改善患 者预后 ...

Core Viewpoint - The Chinese innovative pharmaceutical sector is expected to reach a historical high in 2025 with a total transaction amount exceeding $135.6 billion and an upfront payment of approximately $7 billion, leading to a valuation recovery in the sector [1] Group 1: Market Outlook - The optimistic outlook for the pharmaceutical sector in 2026 is based on the dual logic of global pharmaceutical innovation cycles and the enhancement of China's industrial competitiveness [2][3] - The global pharmaceutical industry is currently experiencing a major innovation cycle, with advancements in gene editing, antibody screening, and targeted drug delivery technologies driving new drug development [2] Group 2: Competitive Position - China's biopharmaceutical industry has entered the global innovative drug competition, with the country ranking second in the global pharmaceutical market and accounting for about 30% of innovative drugs under research [3] - The systemic advantages in R&D efficiency, engineering talent, and clinical resources in China's biopharmaceutical sector are establishing long-term competitive strengths [3] Group 3: Investment Opportunities - The overall valuation recovery in the pharmaceutical sector may be nearing its end, with future investment opportunities likely to arise from structural opportunities with alpha attributes [4] - Four key areas identified for potential alpha generation include next-generation tumor immunotherapy, advancements in antibody-drug conjugates (ADCs), the evolution of weight loss drugs, and the expansion of small nucleic acid drugs into common chronic diseases [4][5] Group 4: AI Integration - AI is enhancing the pharmaceutical sector by improving R&D efficiency, with successful applications in early drug discovery and potential for significant returns by shortening development cycles and reducing costs [7] - The integration of AI tools in drug development is expected to yield substantial benefits during patent protection periods, enhancing project return rates [7] Group 5: Investment Strategy - The investment strategy should focus on selecting assets with unique core competencies, particularly in areas like bispecific antibodies and ADCs, which are globally scarce and in high demand from multinational pharmaceutical companies [8] - The traditional notion that "domestic products are inferior to imports" is being challenged, as China is now competitive in several innovative drug segments [9]

逢低布局港股科技相关ETF：恒生科技指数ETF(513180.SH)、恒生互联网ETF(513330.SH)、港股通科技 ETF基金(159101.SZ)，均在内地交易所上市，且支持T+0日内灵活交易。 其中，恒生互联网ETF(513330.SH)更聚焦港股互联网巨头(阿里巴巴/百度集团/腾讯控股/网易/京东集团 等)；港股通科技ETF基金(159101.SZ)除了覆盖互联网/新能源汽车，还兼顾创新药龙头(百济神州/药明 生物/信达生物等)。 自去年10月以来，恒生科技指数调整时间超80个交易日，回撤幅度已接近20%。该调整时长和调整空 间，均超过历史均值(历史均值：20个交易日，调整幅度-18%) 相比A股科技的优势在于弹性大，港股科技优势则在于韧性强，但AI科技方向整体面临的现状是：短期 受到商业化兑现极度慢的质疑，但长期确定性强。 华夏基金看好港股科技后续反弹空间。板块汇聚国产AI核心资产，涵盖算力、模型、软件应用和硬件 终端等龙头企业，在应用端尤其是互联网与商业场景融合方面具有优势，AI与电商、娱乐、企业服务 的结合有望催生现象级产品。 ...